[Eletriptan shortly before drug approval. Fewer problems in migraine therapy].
D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D005858:Germany; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000188:drug therapy* / Q000209:etiology; D011759:Pyrrolidines / Q000009:adverse effects / Q000627:therapeutic use*; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014363:Tryptamines
D007211:Indoles; D011759:Pyrrolidines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C115647:eletriptan